KAISHA
Lifesciences

Giving Life to Pharmaceutical Innovation

KAISHA
Lifesciences

CONTENTS

01 THE DADACHANJI GROUP OF COMPANIES

02 ABOUT KAISHA LIFESCIENCES

03 OUR CORE COMPETENCIES

04 A GLIMPSE OF OUR FACILITY

05 OUR PRODUCTS

KAISHA
Lifesciences

01

The Dadachanji Group

A Legacy of Innovation

DADACHANJI GROUP

30+ Years of Experience in the Pharmaceutical Industry

Founded by Mr. Kairus Dadachanji and headquartered in Mumbai, India, the Dadachanji Group of Companies is a diversified group with business interests that include Pharmaceuticals and Biotechnology, Primary and Secondary Packaging, Mechanical Devices, Machine Building, Automation, and Robotics.

02

About Kaisha Lifesciences

KAISHA
Lifesciences

Manufacturing the Best of Medicine

1990 — **Kairus Dadachanji** entered the pharmaceutical industry providing tubular glass primary packaging for injectables and went on to build 5+ companies under the **Dadachanji Group.**

2014 — **Kaisha Lifesciences** was established as a young and innovative pharmaceutical company providing safe, effective, quality medical products.

2017 — Kaisha Lifesciences **became fully operational,** continuing to build its own drug pipeline as well as engaging in contract R&D services.

2019 — **DSIR Approval received** for Kaisha Lifesciences.

2021 — **First Indian Patent Approval** for Kaisha Lifesciences.

One Quality for All

As a research-oriented, privately-owned Indian pharmaceutical company engaged in developing, manufacturing, and marketing a broad range of pharmaceutical products across the globe, Kaisha Lifesciences is committed to the highest levels of quality, meeting the exemplary standards of an international pharmaceutical company.

Our philosophy of **'One Quality for All'** helps maintain the highest standards for all our products, which are developed and manufactured under the tightest controls to ensure patient safety. We pride ourselves on instilling the fundamental value of quality in all our employees, which reinforces our commitment to all customers.

KAISHA
Lifesciences

03

Our Core Competencies

KAISHA
Lifesciences

Formulation Development

Committed to continuous research with an aim to improve processes and optimize costs for commercial products. With a plant geared to scale up for batches, we provide quality research and customized services to pharmaceutical companies.

Cover a wide variety of injectable drug products, including solutions for injections, lyophilized powders for injections, Prefilled Syringes, Cartridges and Topical drug products (Gel, Cream & Ointment).

Dedicated team that focusses on development of liposomal drug delivery systems, Depot injections (Microspheres & implants), suspensions for injections, oily injections and IV emulsions.

KAISHA
Lifesciences

Analytical Development

A comprehensive and state-of-the-art Analytical R&D facility with experienced scientists and advanced capabilities to meet the ever-rising demands of the global healthcare industry.

Equipped with a wide range of chromatography and spectroscopic techniques (HPLC, FT-IR, UV, etc.) to meet the requirements of different types of compounds.

60,000 L of storage space with walk-in and reach-in stability chambers including freeze-thaw chambers, stress condition chambers, photostability chambers, and refrigerators. These chambers comply with US FDA 21 CFR with backup units.

All methods developed are fully validated as per the current requirements laid down in the ICH guidelines Q2(R1).

KAISHA
Lifesciences

Quality Assurance and Regulatory Affairs

Maintains cGMP systems following ICH guidelines.

Ensures the latest updates in GMP are being translated into guidelines, standard operating procedures, and protocols.

Ensures these guidelines are implemented to deliver quality products time after time.

Our Regulatory Affairs Department has a strong hand in offering products in Domestic, ROW, Regulated, and Semi-Regulated markets.

KAISHA
Lifesciences

04

A Glimpse of our facility


DADACHANJI GROUP
KAISHA
Lifesciences
Click here to get a glimpse
of our manufacturing facility.

KAISHA
Lifesciences

04

Our Products

Pantoprazole for Injection BP

KAISHA Lifesciences

ZOFAPAN™

ROUTE OF ADMINISTRATION

Intravenous

COMPOSITION: EACH COMBI PACK CONTAINS

A. Pantoprazole for Injection – Each vial contains
Pantoprazole Sodium IP
equivalent to Pantoprazole.....40 mg

B. (For Reconstitution) – Each FFS Ampoule contains:
Sodium Chloride Injection IP (0.9% w/v) 10 mL

INDICATIONS

- Pantoprazole for Injection BP is indicated for short-term treatment (7 to 10 days) of patients with conditions where a rapid reduction of gastric acid secretion is required, such as the following:
  - Reflux esophagitis
  - Gastric and duodenal ulcer
  - Zollinger – Ellison Syndrome and other pathological hypersecretory conditions
- It is an alternative in patients for whom oral administration of Pantoprazole is not indicated.

Esomeprazole Sodium for Injection

KAISHA Lifesciences

ZOFASOM®

ROUTE OF ADMINISTRATION

Intravenous

COMPOSITION: EACH COMBI PACK CONTAINS

A. Esomeprazole Sodium for Injection – Each vial contains
Esomeprazole Sodium Ph. Eur.
equivalent to Esomeprazole.....40 mg

B. (For Reconstitution) – Each FFS Ampoule contains:
Sodium Chloride Injection IP (0.9% w/v) 5 mL

INDICATIONS

- Esomeprazole for injection and infusion is indicated in adults for:
  - Gastric antisecretory treatment when the oral route is not possible, such as:
    - gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux.
    - healing of gastric ulcers associated with NSAID therapy
    - prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.
  - Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
- Esomeprazole for injection and infusion is indicated in children and adolescents aged 1-18 years for:
  - Gastric antisecretory treatment when the oral route is not possible, such as:
    - Gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.

Omeprazole for Injection

KAISHA Lifesciences

ZOFAMEZ®

ROUTE OF ADMINISTRATION

Intravenous

COMPOSITION: EACH COMBI PACK CONTAINS

A. Omeprazole for Injection – Each vial contains:
Omeprazole Sodium BP
equivalent to Omeprazole.....40 mg

B. (For Reconstitution) – Each FFS Ampoule contains:
Sterile Water for Injection IP 10 mL

INDICATIONS

- As an alternative to oral therapy for the following indications:
  - Treatment of duodenal ulcers
  - Prevention of relapse of duodenal ulcers
  - Treatment of gastric ulcers
  - Prevention of relapse of gastric ulcers
  - In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic ulcer disease
  - Treatment of NSAID-associated gastric and duodenal ulcers
  - Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk
  - Treatment of reflux esophagitis
  - Long-term management of patients with healed reflux esophagitis
  - Treatment of symptomatic gastro-esophageal reflux disease
  - Treatment of Zollinger-Ellison syndrome

Rabeprazole Injection IP

KAISHA Lifesciences

ZOFARAB®

ROUTE OF ADMINISTRATION

Intravenous

COMPOSITION – EACH COMBI PACK CONTAINS

A. <u>One Vial of Rabeprazole Injection – Each vial contains</u>
Rabeprazole Sodium IP…..20mg

B. <u>For Reconstitution – Each FFS Ampoule contains</u>
Sterile Water for Injection IP….5 mL

INDICATIONS

- An alternative in patients for whom oral administration of Rabeprazole is not indicated. Rabeprazole Injection IP is indicated in the treatment of:
  - Gastric and duodenal ulcer
  - Gastroesophageal Reflux Disease (GERD)
  - As an alternative to oral therapy in patients who are unable to take proton-pump inhibitor
  - Prevention of acid-aspiration
  - Stress-induced mucosal injury in critical care
  - Pathological hyper secretory conditions including Zollinger-Ellison syndrome.

Ondansetron Injection IP 2mg/ml (2 ml and 4 ml)

KAISHA Lifesciences

SOVESET® 2 ml

SOVESET® 4 ml

ROUTE OF ADMINISTRATION

Intravenous/Intramuscular

COMPOSITION: EACH ML CONTAINS:

Ondansetron Hydrochloride IP equivalent to Ondansetron.....2mg
Water for Injections.....q.s.

INDICATIONS

- Intravenously administered ondansetron injection formulations are indicated for:
  - Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (i.e., greater than or equal to 50 mg/m^2) cisplatin therapy.
- Ondansetron injection and infusion are indicated for:
  - Prevention of post-operative nausea and/or vomiting. As with other anti-emetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur post-operatively. In patients in whom nausea and/or vomiting must be avoided post-operatively, ondansetron injection is recommended even when the incidence of post-operative nausea and/or vomiting is low. For patients who do not receive prophylactic ondansetron injection and experience nausea and/or vomiting post-operatively, ondansetron injection may be given to prevent further episodes.

Enoxaparin Sodium Injection I.P. 300mg/3ml

KAISHA Lifesciences



KAIVEXIN® - 300

ROUTE OF ADMINISTRATION
Subcutaneous

COMPOSITION: EACH MULTI-DOSE CARTRIDGE CONTAINS
Enoxaparin Sodium I.P....300mg/3mL
(Porcine derived)
Phenol I.P....0.25% w/v
(as preservative)
Water for Injections I.P.....q.s.

INDICATIONS

- Prophylaxis of thromboembolic disorders of venous origin, in particular those which may be associated with orthopaedic or general surgery.
- Prophylaxis of venous thromboembolism in medical patients bedridden due to acute illnesses including cardiac insufficiency, respiratory failure, or severe infections.
- Treatment of venous thromboembolic disease presenting with deep vein thrombosis, pulmonary embolism or both.
- Treatment of unstable angina and non-Q-wave myocardial infarction administered concurrently with aspirin.
- Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI).
- Prevention of thrombus formation in the extracorporeal circulation during haemodialysis.

Enoxaparin Sodium Injection I.P.

ROUTE OF ADMINISTRATION

Intravenous/Intravascular

COMPOSITION – EACH PRE-FILLED SYRINGE CONTAINS

Enoxaparin Sodium I.P....20mg | 40 mg | 60 mg | 80 mg (Porcine derived)

Equivalent to 2000 IU | 4000 IU | 6000 IU | 8000 IU of Anti-factor Xa Activity

Water for Injections I.P....
q.s. to 0.2 mL | 0.4 mL | 0.6 mL | 0.8 mL

INDICATIONS

- Prophylaxis of thromboembolic disorders of venous origin, in particular those
  which may be associated with orthopaedic or general surgery.
- Prophylaxis of venous thromboembolism in medical patients bedridden due to acute illnesses including cardiac insufficiency, respiratory failure, or severe infections.
- Treatment of venous thromboembolic disease presenting with deep vein thrombosis, pulmonary embolism or both.
- Treatment of unstable angina and non-Q-wave myocardial infarction administered concurrently with aspirin.
- Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI).
- Prevention of thrombus formation in the extracorporeal circulation during haemodialysis.

DADACHANJI GROUP

KAISHA Packaging | KAISHA Lifesciences | KAISHA Packwell

KAIRISH Innotech | KAIRISH Shared Services | DADACHANJI AVIATION

SOVEVAX BIOLOGICS | SOVEREIGN

Manufacturing Site
Survey No. 342/3 (77), Bharat Industrial Estate, Bhimpore, Nani Daman (U.T.), Daman - 396210, India.

Registered Address
72-73, 7th Floor, Plot 215, Free Press House, Free Press Journal Marg, Nariman Point, Mumbai, Maharashtra - 400021, India.

www.kaishalifesciences.com

info@kaishalifesciences.com